Advantage of postoperative oral administration of UFT (Tegafur and Uracil) for completely resected p-Stage I-IIIa non-small cell lung cancer (NSCLC)

By Maggi G.   Ruffini E.  

European Journal of Cardio-Thoracic Surgery, Vol. 14, Iss. 3, 1998-09 ,pp. : 263-264

Elsevier

Access to resources Recommend Favorite

Postoperative adjuvant chemotherapy with PVM (Cisplatin+Vindesine+Mitomycin C) and UFT (Uracil+Tegaful) in resected stage I-II NSCLC (non-small cell lung cancer): a randomized clinical trial

By Wada H.   Miyahara R.   Tanaka F.   Hitomi S.  

European Journal of Cardio-Thoracic Surgery, Vol. 15, Iss. 4, 1999-04 ,pp. : 438-443

Elsevier

Access to resources Recommend Favorite

Time trends and survival after surgery for p-stage IIIa, pN2 non-small cell lung cancer (NSCLC)

By Tanaka F.   Yanagihara K.   Ohtake Y.   Fukuse T.   Hitomi S.   Wada H.  

European Journal of Cardio-Thoracic Surgery, Vol. 12, Iss. 3, 1997-09 ,pp. : 372-379

Elsevier

Access to resources Recommend Favorite

Prognostic significance of E-cadherin and -catenin in resected stage I non-small cell lung cancer

By Soo Choi Y.   Mog Shim Y.   Kim S.-H.   Soon Son D.   Lee H.-S.   Young Kim G.   Han J.   Kim J.  

European Journal of Cardio-Thoracic Surgery, Vol. 24, Iss. 3, 2003-09 ,pp. : 441-449

Elsevier

Access to resources Recommend Favorite

Prognostic factors in patients with resected pathologic (p-) T1-2N1M0 non-small cell lung cancer (NSCLC)

By Tanaka F.   Yanagihara K.   Otake Y.   Yamada T.   Shoji T.   Miyahara R.   Inui K.   Wada H.  

European Journal of Cardio-Thoracic Surgery, Vol. 19, Iss. 5, 2001-05 ,pp. : 555-561

Elsevier

Access to resources Recommend Favorite